Stockreport

Beam Therapeutics (BEAM) Reveals Encouraging Results From Risto-Cel Phase 1/2 BEACON Study [Yahoo! Finance]

Beam Therapeutics Inc.  (BEAM) 
PDF On April 2, Beam Therapeutics Inc. (NASDAQ:BEAM) released results from its Phase 1/2 BEACON study for ristoglogene autogetemcel. This therapy is being developed to trea [Read more]